These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32354945)

  • 1. Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
    Shintani D; Yoshida H; Yabuno A; Fujiwara K
    In Vivo; 2020; 34(3):1451-1457. PubMed ID: 32354945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Bevacizumab on Clinical Outcomes in Patients With Platinum-resistant Relapsed Ovarian Cancer.
    Seol A; Kim SI; Yoon HY; Lee M; Kim HS; Chung HH; Park NH; Song YS
    In Vivo; 2024; 38(3):1338-1350. PubMed ID: 38688599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous Administration of Bevacizumab After Disease Progression in Recurrent Ovarian Cancer: A Retrospective Observational Study.
    Tanigawa T; Matoda M; Omi M; Aoki Y; Netsu S; Nomura H; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Takeshima N
    Anticancer Res; 2020 Sep; 40(9):5285-5290. PubMed ID: 32878818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
    Wu YS; Shui L; Shen D; Chen X
    Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer.
    Garcia Garcia Y; de Juan Ferré A; Mendiola C; Barretina-Ginesta MP; Gaba Garcia L; Santaballa Bertrán A; Bover Barcelo I; Gil-Martin M; Manzano A; Rubio Pérez MJ; Romeo Marin M; Arqueros Núñez C; García-Martínez E; Gonzalez Martin A
    Int J Gynecol Cancer; 2019 Jul; 29(6):1050-1056. PubMed ID: 31263024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
    Haunschild CE; Tewari KS
    Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab Efficacy and Recurrence Pattern of Persistent and Metastatic Cervical Cancer.
    Lee N; Kim SI; Lee M; Kim HS; Kim JW; Park NH; Song YS
    In Vivo; 2019; 33(3):863-868. PubMed ID: 31028209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of progression-free and overall survival in ovarian cancer: Bevacizumab treatment outcomes using historical cohort.
    Conic I; Nedovic B; Zivadinovic R; Zivadinovic R; Petric A; Stojnev S; Petkovic I; Krtinic D; Radic M
    Pharmazie; 2024 Oct; 79(9):195-201. PubMed ID: 39407422
    [No Abstract]   [Full Text] [Related]  

  • 10. Safety and Efficacy of Extended Bevacizumab Therapy in Elderly (≥70 Years) Versus Younger Patients Treated for Newly Diagnosed Ovarian Cancer in the International ROSiA Study.
    Selle F; Colombo N; Korach J; Mendiola C; Cardona A; Ghazi Y; Oza AM
    Int J Gynecol Cancer; 2018 May; 28(4):729-737. PubMed ID: 29498983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer.
    Zhang W; Shen Z; Luo H; Hu X; Zheng L; Zhu X
    Curr Drug Targets; 2017; 18(10):1125-1131. PubMed ID: 27138763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma.
    Cha Y; Kim YJ; Lee SH; Kim TM; Choi SH; Kim DW; Park CK; Kim IH; Kim JH; Kim E; Choi B; Kim CY; Kim IA; Heo DS
    Cancer Res Treat; 2017 Jan; 49(1):129-140. PubMed ID: 27188199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world use of bevacizumab in metastatic colorectal, metastatic breast, advanced ovarian and cervical cancer: a systematic literature review.
    Raouf S; Bertelli G; Ograbek A; Field P; Tran I
    Future Oncol; 2019 Feb; 15(5):543-561. PubMed ID: 30379088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delta tocotrienol in recurrent ovarian cancer. A phase II trial.
    Thomsen CB; Andersen RF; Steffensen KD; Adimi P; Jakobsen A
    Pharmacol Res; 2019 Mar; 141():392-396. PubMed ID: 30639384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term survival and renal dysfunction in a patient with recurrent colorectal cancer treated with Bevacizumab.
    Kataoka S; Nishikawa Y; Funakoshi T; Horimatsu T; Kondo N; Matsubara T; Yanagita M; Matsumoto S; Muto M
    Clin J Gastroenterol; 2020 Jun; 13(3):316-319. PubMed ID: 31707696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study.
    Chikazawa K; Netsu S; Kuwata T; Konno R
    Taiwan J Obstet Gynecol; 2018 Dec; 57(6):819-824. PubMed ID: 30545534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    Poveda AM; Selle F; Hilpert F; Reuss A; Savarese A; Vergote I; Witteveen P; Bamias A; Scotto N; Mitchell L; Pujade-Lauraine E
    J Clin Oncol; 2015 Nov; 33(32):3836-8. PubMed ID: 26282651
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
    Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
    Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
    Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
    Nanki Y; Nomura H; Iwasa N; Saotome K; Dozen A; Yoshihama T; Hirano T; Hashimoto S; Chiyoda T; Yamagami W; Kataoka F; Aoki D
    Jpn J Clin Oncol; 2021 Jan; 51(1):54-59. PubMed ID: 32776094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.